MedPath

Bala Taila Matra Basti in the management of Mootraghata(Benign Prostatic Hyperplasia

Phase 2
Completed
Conditions
Benign prostatic hyperplasia without lower urinary tract symptoms. Ayurveda Condition: MUTRAGHATAH,
Registration Number
CTRI/2020/12/030110
Lead Sponsor
Institute for Post Graduate Teaching and Research in Ayurveda Gujrat Ayurved University
Brief Summary

In the clinical study, atotal of 40 patients with BPH were selected and divided randomly into twogroups In group-A treated with *VarunashigravaadiGhanavati* with *Bala Taila Matra* and In group B was treated with CapsuleTamsulosin (0.4 mg) orally. Both groups divided according to acomputer-generate randomization chart among them 40 patients completed thetreatment as well as follow up. All the patients were assessed as persubjective and objective criteria adopted during the study and the findingswere recorded in the research proforma.

In group-A *Varunashigravaadi Ghanavati* with *BalaTaila Matra Basti*, highly significant result was observed in average urineflow rate (UFR), enlarged prostate size & volume whereas no significantresult was found in post voidal residual urine (PVRU) volume.

Ingroup B Capsule Tamsulosin (0.4 mg) orally, highly significant result was observedin Objective parameters i.e., average urine flow rate (UFR), size of theenlarged prostate & prostate volume, and post voidal residual urine (PVRU) volume.

Statistically,a significant result was noted on Subjective Parameter i.e. increasedfrequency, nocturia, weak stream, incomplete voiding, and urgency in thepatients of both groups.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
40
Inclusion Criteria

The patients between 50-70 years of age The patients having 3 or more than 3 signs and symptoms of Mootraghata(Benign Prostatic Hyperplasia) Controlled Hypertension (BP less than 150-90 mmHg), diabetes mellitus (RBS less than 140 mg/dl).

Exclusion Criteria

Patients of age below 50 years and above 70 years Patients of malignancy, congenital deformities of urogenital tract or any abdominal-pelvic pathology other than BPH Systemic diseases like chronic renal failure (CRF), Uncontrolled Hypertension (BP>150-90), diabetes mellitus (RBS >140) Patients having Hematuria(Blood in the urine) , Bladder infection(UTI), kidney stone, Bladder stone PSA level above 4.0 ng/ml Patients k/c/o Tuberculosis, Paralysis, and Parkinsonism will be excluded Known case of cardiac diseases (H/o- MI, IHD).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prostate size reduced4 weeks
decrease in PSA level4 weeks
Secondary Outcome Measures
NameTimeMethod
Improvement in sign and symptoms of BPH and also improvement in quality of life4 weeks

Trial Locations

Locations (1)

Institute for Post Graduate Teaching and Research in Ayurveda GAU Jamnagar 361008

🇮🇳

Jamnagar, GUJARAT, India

Institute for Post Graduate Teaching and Research in Ayurveda GAU Jamnagar 361008
🇮🇳Jamnagar, GUJARAT, India
Ashish J Talsaniya
Principal investigator
7984969783
ajtalsaniya32@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.